Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc..
Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB). The ability of ICB to prevent dMMR malignant or pre-malignant neoplasia development in patients with Lynch syndrome (LS) is unknown. Of 172 cancer-affected patients with LS who had received ≥1 ICB cycles, 21 (12%) developed subsequent malignancies after ICB exposure, 91% (29/32) of which were dMMR, with median time to development of 21 months (interquartile range, 6-38). Twenty-four of 61 (39%) ICB-treated patients who subsequently underwent surveillance colonoscopy had premalignant polyps. Within matched pre-ICB and post-ICB follow-up periods, the overall rate of tumor development was unchanged; however, on subgroup analysis, a decreased incidence of post-ICB visceral tumors was observed. These data suggest that ICB treatment of LS-associated tumors does not eliminate risk of new neoplasia development, and LS-specific surveillance strategies should continue. These data have implications for immunopreventative strategies and provide insight into the immunobiology of dMMR tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 10 vom: 14. Okt., Seite 2458-2463 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Harrold, Emily C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.11.2023 Date Revised 20.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02544-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363382410 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363382410 | ||
| 003 | DE-627 | ||
| 005 | 20240420232153.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02544-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM363382410 | ||
| 035 | |a (NLM)37845474 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Harrold, Emily C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2023 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB). The ability of ICB to prevent dMMR malignant or pre-malignant neoplasia development in patients with Lynch syndrome (LS) is unknown. Of 172 cancer-affected patients with LS who had received ≥1 ICB cycles, 21 (12%) developed subsequent malignancies after ICB exposure, 91% (29/32) of which were dMMR, with median time to development of 21 months (interquartile range, 6-38). Twenty-four of 61 (39%) ICB-treated patients who subsequently underwent surveillance colonoscopy had premalignant polyps. Within matched pre-ICB and post-ICB follow-up periods, the overall rate of tumor development was unchanged; however, on subgroup analysis, a decreased incidence of post-ICB visceral tumors was observed. These data suggest that ICB treatment of LS-associated tumors does not eliminate risk of new neoplasia development, and LS-specific surveillance strategies should continue. These data have implications for immunopreventative strategies and provide insight into the immunobiology of dMMR tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Foote, Michael B |e verfasserin |4 aut | |
| 700 | 1 | |a Rousseau, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Walch, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Kemel, Yelena |e verfasserin |4 aut | |
| 700 | 1 | |a Richards, Allison L |e verfasserin |4 aut | |
| 700 | 1 | |a Keane, Fergus |e verfasserin |4 aut | |
| 700 | 1 | |a Cercek, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Yaeger, Rona |e verfasserin |4 aut | |
| 700 | 1 | |a Rathkopf, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Segal, Neil H |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Zalak |e verfasserin |4 aut | |
| 700 | 1 | |a Maio, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Borio, Matilde |e verfasserin |4 aut | |
| 700 | 1 | |a O'Reilly, Eileen M |e verfasserin |4 aut | |
| 700 | 1 | |a Reidy, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Avni |e verfasserin |4 aut | |
| 700 | 1 | |a Janjigian, Yelena Y |e verfasserin |4 aut | |
| 700 | 1 | |a Murciano-Goroff, Yonina R |e verfasserin |4 aut | |
| 700 | 1 | |a Carlo, Maria I |e verfasserin |4 aut | |
| 700 | 1 | |a Latham, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ying L |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Michael F |e verfasserin |4 aut | |
| 700 | 1 | |a Ilson, David |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenberg, Jonathan E |e verfasserin |4 aut | |
| 700 | 1 | |a Markowitz, Arnold J |e verfasserin |4 aut | |
| 700 | 1 | |a Weiser, Martin R |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Anthony M |e verfasserin |4 aut | |
| 700 | 1 | |a Vanderbilt, Chad |e verfasserin |4 aut | |
| 700 | 1 | |a Mandelker, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Bandlamudi, Chaitanya |e verfasserin |4 aut | |
| 700 | 1 | |a Offit, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Michael F |e verfasserin |4 aut | |
| 700 | 1 | |a Solit, David B |e verfasserin |4 aut | |
| 700 | 1 | |a Saltz, Leonard |e verfasserin |4 aut | |
| 700 | 1 | |a Shia, Jinru |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz, Luis A |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Stadler, Zsofia K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 10 vom: 14. Okt., Seite 2458-2463 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:10 |g day:14 |g month:10 |g pages:2458-2463 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02544-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 10 |b 14 |c 10 |h 2458-2463 | ||